Development of semisynthetic blasticidin S analogs with potent and fast-killing anti-malarial activity

preprint OA: closed CC-BY-NC-ND-4.0
AI-generated deep summary by claude@2026-06, 2026-06-24 · read from full text

This paper studied whether semisynthetic analogs of blasticidin S, modified at the C6’ and C4 positions, could improve antimalarial potency and selectivity by targeting the ribosomal peptidyl transferase center. Across cultured Plasmodium falciparum drug-sensitive and -resistant lines, two lead analogs were reported to be two orders of magnitude more potent than blasticidin S while showing low cytotoxicity toward mammalian cells, with faster inhibition kinetics of parasite protein synthesis and markedly improved speed of killing. The analogs also blocked development of asexual stages expressing the plasmodial surface anion channel, a transporter required for nutrient acquisition and blasticidin S uptake, and docking analyses suggested increased interactions at the peptidyl transferase center consistent with higher potency. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 2,068 characters · extracted from oa-html · click to expand
ABSTRACT Protein synthesis represents an attractive target space for the development of anti-malarials with novel modes of action. Natural-product inhibitors of the eukaryotic 80S ribosome can have potent anti-malarial activity but are often poorly selective due to mammalian cytotoxicity. Blasticidin S (BlaS) is a microbially-produced natural product that broadly inhibits prokaryotic and eukaryotic protein synthesis by binding to the ribosomal peptidyl transferase center. In this study, we explored the potential for improving the anti-malarial potency and selectivity of the blasticidin S scaffold with semi-synthetic analogs that are modified at the C6’ and C4 sites. The two best analogs were two orders of magnitude more potent than BlaS against Plasmodium falciparum drug-sensitive and -resistant lines while displaying low cytotoxicity towards mammalian cells. These analogs exhibited improved kinetics of inhibition of protein synthesis in cultured parasites and blocked the development of asexual stages expressing the plasmodial surface anion channel, a transporter required for nutrient acquisition and BlaS uptake. They also exhibited a dramatically improved speed of killing over BlaS. Molecular docking analysis revealed that these analogs are able to form more interactions with the P. falciparum ribosomal peptidyl transferase center than is BlaS, which is consistent with their increased potency. Together, these studies demonstrate the feasibility of generating BlaS analogs with potent anti-malarial activity and provide a roadmap for further development. Competing Interest Statement The authors have declared no competing interest. ABBREVIATIONS - ACT - artemisinin combination therapy - BlaS - blasticidin S - CQ - chloroquine - DMSO - dimethylsulfoxide; - HPG - homopropargylglycine - hpi - hours post-invasion - PABA - para-aminobenzoic acid - PfCRT - P. falciparum chloroquine resistance transporter - PfMDR1 - P. falciparum multi-drug resistance transporter 1 - PSAC - plasmodial surface anion channel - PTC - peptidyl transferase center.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-05-23T02:00:01.238055+00:00
License: CC-BY-NC-ND-4.0